Liu Qiaomei, Xiong Wei
Pain Rehabilitation Department, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, 430060, China.
Department of Thyroid and Breast Surgery, Hubei Provincial Hospital of TCM, Hubei Shizhen Laboratory, No. 4 Garden Hill, Rouge Road, Wuchang District, Wuhan, 430061, China.
Discov Oncol. 2025 May 2;16(1):655. doi: 10.1007/s12672-025-02483-6.
Breast cancer is the most prevalent malignancy among women, it is crucial to identify sensitive biomarkers for prognosis and treatment of breast cancer patients. Emerging research has demonstrated the involvement of long noncoding RNAs (lncRNAs) in the advancement of breast cancer. LINC00534 has recently emerged as a potential regulator in multiple malignancies, yet its clinical significance and molecular mechanisms in breast cancer remain poorly characterized.
The purpose of this study was to explore the function of LINC00534 and miR-139-5p in breast cancer progression, as well as the mechanisms that underpin its actions.
Tumor and normal tissues were collected from 80 breast cancer patients. qRT-PCR was performed to detect LINC00534 expression in tissues. Kaplan-Meier analysis was used to assess survival differences between groups and the correlation between LINC00534 expression and clinical outcomes. CCK-8 assay was used to evaluate cell proliferation to assess LINC00534's effect on tumor growth. To evaluate the impact of LINC00534 on tumor metastasis, transwell assay was used to detect the migration and invasion abilities of cells. Moreover, dual-luciferase assay was used to verify the relationship within the LINC00534/miR-139-5p/HMGB2 axis.
LINC00534 was significantly upregulated in breast cancer tumor tissues and cell lines (p < 0.001). Higher LINC00534 expression correlated with poorer prognosis in breast cancer patients, including shorter survival and higher recurrence risk (Log-rank p = 0.014). Furthermore, LINC00534 promoted breast cancer cell proliferation, migration, and invasion (all p < 0.001) via its interaction with the miR-139-5p/HMGB2 axis.
LINC00534 may serve as a prognostic marker and the LINC00534/miR-139-5p/HMGB2 axis could be a therapeutic target for breast cancer.
乳腺癌是女性中最常见的恶性肿瘤，识别用于乳腺癌患者预后和治疗的敏感生物标志物至关重要。新兴研究表明长链非编码RNA（lncRNA）参与了乳腺癌的进展。LINC00534最近已成为多种恶性肿瘤中的潜在调节因子，但其在乳腺癌中的临床意义和分子机制仍不清楚。
本研究旨在探讨LINC00534和miR-139-5p在乳腺癌进展中的作用及其作用机制。
收集80例乳腺癌患者的肿瘤组织和正常组织。采用qRT-PCR检测组织中LINC00534的表达。采用Kaplan-Meier分析评估各组之间的生存差异以及LINC00534表达与临床结局之间的相关性。采用CCK-8法评估细胞增殖，以评估LINC00534对肿瘤生长的影响。为了评估LINC00534对肿瘤转移的影响，采用Transwell法检测细胞的迁移和侵袭能力。此外，采用双荧光素酶报告基因检测法验证LINC00534/miR-139-5p/HMGB2轴之间的关系。
LINC00534在乳腺癌肿瘤组织和细胞系中显著上调（p < 0.001）。LINC00534表达较高与乳腺癌患者预后较差相关，包括生存期较短和复发风险较高（对数秩检验p = 0.014）。此外，LINC00534通过与miR-139-5p/HMGB2轴相互作用促进乳腺癌细胞增殖、迁移和侵袭（所有p < 0.001）。
LINC00534可能作为一种预后标志物，LINC00534/miR-139-5p/HMGB2轴可能成为乳腺癌的治疗靶点。
